An experimental regimen of low-dose thalidomide and the steroid prednisone was effective against anemia and thrombocytopenia in a three-month pilot study enrolling 21 patients who had myelofibrosis with myeloid metaplasia (MMM).
Ruben A. Mesa, MD, and his colleagues at the Mayo Clinic in Rochester, Minnesota, were able to palliate anemia in 62% and thrombocytopenia in 75% of the patients. Activity against splenomegaly was more limited; four patients had a >50% reduction in spleen size.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!